MARKSANS PHARMA LTD.
P&L
Quarterly Consolidated
vs Q3 FY26
Marksans Pharma FY26: Revenue ₹3,033 Cr, PAT ₹420 Cr
26 May 2026 · 26 May, 1:33 pm
Summary
Marksans Pharma Ltd. reported a milestone FY26, achieving its highest-ever total income of ₹3,033 crore, up 12.8% year-over-year, alongside record EBITDA of ₹601 crore with a 20.4% margin and PAT of ₹420 crore, a 9.8% increase. Q4FY26 also demonstrated strong performance with total income growing 23.1% to ₹891 crore and EBITDA surging 54.0% to ₹195 crore. Managing Director Mark Saldanha highlighted that the company successfully delivered on its guidance, driven by new product launches and market expansion, while maintaining a robust cash balance of ₹990 crore.
Key Highlights
- 1
Marksans Pharma achieved its highest-ever total income of ₹3,033 crore for FY26, marking a 12.8% year-over-year increase.
- 2
The company's EBITDA for FY26 reached ₹601 crore, with a healthy EBITDA margin of 20.4%, also its highest-ever.
- 3
Profit After Tax (PAT) for FY26 hit an all-time high of ₹420 crore, representing a 9.8% growth year-over-year.
- 4
For Q4FY26, total income significantly grew by 23.1% year-over-year to ₹891 crore.
- 5
Q4FY26 EBITDA saw a substantial surge of 54.0% year-over-year, reaching ₹195 crore with an EBITDA margin of 22.8%.
- 6
The company maintained a strong cash balance of ₹990 crore as of March 31, 2026, extending its multi-year track record of being net cash positive.
- 7
The UK & Europe business delivered a strong recovery in Q4, achieving its highest-ever quarterly revenue of ₹308 crore, complemented by the highest-ever quarterly performance from Australia and New Zealand at ₹123 crore.
Management Comments
Mark Saldanha
FY26 has been a milestone year for Marksans Pharma, we successfully delivered on our guidance with highest-ever total income at ~₹3,033 crore, EBITDA at ₹601 crore (margin 20.4%) and an all-time high PAT of ₹420 crore. Growth was led by a series of new launches across markets through the year, including our Rx branded portfolio in Australia. UK delivered a very strong recovery in Q4 achieving its highest-ever quarterly revenue. Growth was also aided by 112 new SKUs launched in the US market. We also strengthened our global footprint by entering new markets including Germany, Canada, and Ireland. We closed the year with a cash balance of ~₹990 crore, extending our multi-year track record of net cash positive, with the major capex cycle now nearly complete. While we are monitoring emerging input cost pressures closely, our underlying momentum, balance sheet strength, and disciplined execution position us well to continue delivering sustainable growth and long-term shareholder value.
Informational and educational content only. Not investment advice.